Sec. 3004. REPORT ON PATIENT EXPERIENCE DRUG DEVELOPMENT

120 words·~1 min read·/statute-compilations/comps-13005/sec-3004

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

## SEC. 3004 REPORT ON PATIENT EXPERIENCE DRUG DEVELOPMENT **[**[21 U.S.C. 355 note](/us/usc/t21/s355)**]** Not later than June 1 of 2021, 2026, and 2031, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall prepare and publish on the Internet website of the Food and Drug Administration a report assessing the use of patient experience data in regulatory decisionmaking, in particular with respect to the review of patient experience data and information on patient-focused drug development tools as part of applications approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(c)) or section 351(a) of the Public Health Service Act (42 U.S.C. 262(a)). ## Subtitle B Advancing New Drug Therapies

Connectionstraces to 2

Traces to 2 documents

U.S. Code

Citation graph

cites case law

Sec. 3004

REPORT ON PATIENT EXPERIENCE DRUG DEVELOPMENT

U.S.C.§ 355

U.S.C.§ 262

Cites 2Cited by 0 across 0 sources